Suzhou Basecare Medical Corporation Limited (BASECARE-B) disclosed that it repurchased 15,000 H-shares on 12 October 2026, representing 0.02% of its issued share capital (excluding treasury shares) prior to the transaction.

The shares were bought on the Hong Kong Stock Exchange at prices ranging from HKD 1.28 to HKD 1.30, for an aggregate outlay of HKD 19,395, implying an average repurchase price of HKD 1.29 per share.

Post-transaction, the company’s outstanding share count (excluding treasury shares) fell to 82.68 million, while treasury shares increased to 30,000. The total issued share capital remains unchanged at 82.71 million shares.

The buyback was executed under the repurchase mandate granted on 4 June 2026, which authorises the company to repurchase up to 8.27 million shares. Cumulative repurchases under this mandate now total 30,000 shares, equivalent to 0.04% of the issued share base at the time the mandate was approved.

In line with Hong Kong listing rules, BASECARE-B is subject to a moratorium on issuing new shares or selling treasury shares until 11 November 2026. The company confirmed that the repurchase complied with all relevant Main Board Listing Rules and that no material changes have been made to the explanatory statement filed on 12 May 2026.